Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Intellia Therapeutics (NTLA) Operating Expenses (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Operating Expenses for 11 consecutive years, with $121.7 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses fell 18.48% to $121.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $508.7 million through Dec 2025, down 14.1% year-over-year, with the annual reading at $508.7 million for FY2025, 14.1% down from the prior year.
  • Operating Expenses for Q4 2025 was $121.7 million at Intellia Therapeutics, down from $125.3 million in the prior quarter.
  • The five-year high for Operating Expenses was $155.5 million in Q1 2022, with the low at $52.9 million in Q1 2021.
  • Average Operating Expenses over 5 years is $123.2 million, with a median of $124.9 million recorded in 2023.
  • The sharpest move saw Operating Expenses skyrocketed 194.11% in 2022, then decreased 19.89% in 2023.
  • Over 5 years, Operating Expenses stood at $93.3 million in 2021, then soared by 32.58% to $123.7 million in 2022, then rose by 11.58% to $138.0 million in 2023, then rose by 8.22% to $149.3 million in 2024, then decreased by 18.48% to $121.7 million in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $121.7 million, $125.3 million, and $124.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.